These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 8509348)

  • 1. Low-dose oral medroxyprogesterone acetate in the management of the paraphilias.
    Gottesman HG; Schubert DS
    J Clin Psychiatry; 1993 May; 54(5):182-8. PubMed ID: 8509348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medroxyprogesterone treatment for paraphiliacs.
    Kravitz HM; Haywood TW; Kelly J; Wahlstrom C; Liles S; Cavanaugh JL
    Bull Am Acad Psychiatry Law; 1995; 23(1):19-33. PubMed ID: 7599368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medroxyprogesterone and paraphiles: do testosterone levels matter?
    Kravitz HM; Haywood TW; Kelly J; Liles S; Cavanaugh JL
    Bull Am Acad Psychiatry Law; 1996; 24(1):73-83. PubMed ID: 8891323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depo provera treatment for sex offending behavior: an evaluation of outcome.
    Meyer WJ; Cole C; Emory E
    Bull Am Acad Psychiatry Law; 1992; 20(3):249-59. PubMed ID: 1421556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug treatment of paraphilic and nonparaphilic sexual disorders.
    Guay DR
    Clin Ther; 2009 Jan; 31(1):1-31. PubMed ID: 19243704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing antilibidinal treatment with medroxyprogesterone acetate.
    Stewart JT
    J Am Geriatr Soc; 2005 Feb; 53(2):359-60. PubMed ID: 15673373
    [No Abstract]   [Full Text] [Related]  

  • 7. Medroxyprogesterone acetate treatment reduces serum interleukin-6 levels in patients with metastatic breast carcinoma.
    Yamashita J; Hideshima T; Shirakusa T; Ogawa M
    Cancer; 1996 Dec; 78(11):2346-52. PubMed ID: 8941005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical investigation of oral high-dose medroxyprogesterone acetate (MPA) in advanced breast cancer--double-blind controlled study: Japanese Group for MPA Treatment of Breast Cancer].
    Izuo M; Tominaga T; Yoshida M; Nomura Y; Abe O; Enomoto K; Kubo K; Takatani O
    Gan No Rinsho; 1985 May; 31(5):487-93. PubMed ID: 3160869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral high-dose medroxyprogesterone acetate treatment for recurrent breast cancer.
    Iino Y; Takeo T; Sugamata N; Aoyagi H; Takai Y; Takei H; Ando T; Koibuchi Y; Yokoe T; Ohwada S
    Anticancer Res; 1995; 15(3):1061-4. PubMed ID: 7645926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical pharmacokinetics and practical consequences of optimal use of medroxyprogesterone acetate].
    Etienne MC; Milano G; Namer M
    Bull Cancer; 1993 May; 80(5):431-8. PubMed ID: 8173196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy.
    Mantovani G; Macciò A; Madeddu C; Mulas C; Massa E; Astara G; Ferreli L; Mudu MC; Gramignano G; Murgia V; Lusso MR; Mocci M; Cardia A; Mura L
    Oncol Rep; 2002; 9(4):887-96. PubMed ID: 12066227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depo Provera. Position paper on clinical use, effectiveness and side effects.
    Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
    Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A comparative study between low-dose and high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer--in relation to dose, serum concentration and response. Osaka Breast Cancer Research Group].
    Furukawa J; Yayoi E; Takatsuka Y; Aikawa T; Maeura Y; Kobayashi T; Miyauchi K; Kotsuma Y
    Gan To Kagaku Ryoho; 1997 May; 24(7):815-21. PubMed ID: 9170519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy (recombinant interleukin 2), hormone therapy (medroxyprogesterone acetate) and antioxidant agents as combined maintenance treatment of responders to previous chemotherapy.
    Mantovani G; Maccio A; Madeddu C; Massa E; Mudu MC; Mulas C; Gramignano G; Massidda S; Murgia V; Lusso MR; Mura L
    Int J Oncol; 2001 Feb; 18(2):383-91. PubMed ID: 11172608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of obsessive homosexual pedophilic fantasies with medroxyprogesterone acetate.
    Pinta ER
    Biol Psychiatry; 1978 Jun; 13(3):369-73. PubMed ID: 667234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer.
    Mantovani G; Macciò A; Mulas C; Massa E; Madeddu C; Mura L; Contu P; Versace R
    Oncol Rep; 2002; 9(3):661-70. PubMed ID: 11956647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of four different regimens of hormone replacement therapy on hemostatic parameters: a prospective randomized study.
    Taner MZ; Ozpolat E; Taskiran C; Onan MA; Gursel T; Karabulut E; Gursoy R; Himmetoglu O
    Maturitas; 2006 Feb; 53(3):267-73. PubMed ID: 15978753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endogenous serum testosterone in males after different doses and routes of administration of medroxyprogesterone acetate.
    Novak E; Hendrix JW; Seckman CE; Kaiser DG; Stoll RG
    J Reprod Med; 1980 Oct; 25(4):157-60. PubMed ID: 7431362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progesterone and medroxyprogesterone acetate effects on central and peripheral allopregnanolone and beta-endorphin levels.
    Bernardi F; Pluchino N; Pieri M; Begliuomini S; Lenzi E; Puccetti S; Casarosa E; Luisi M; Genazzani AR
    Neuroendocrinology; 2006; 83(5-6):348-59. PubMed ID: 16931878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative.
    Barnabei VM; Cochrane BB; Aragaki AK; Nygaard I; Williams RS; McGovern PG; Young RL; Wells EC; O'Sullivan MJ; Chen B; Schenken R; Johnson SR;
    Obstet Gynecol; 2005 May; 105(5 Pt 1):1063-73. PubMed ID: 15863546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.